Previous Close | 3.36 |
1-Year Change | 42.37% |
6-Months Change | -7.18% |
3-Months Change | -14.29% |
Moving Avg (50d) | 3.377 |
Moving Avg (200d) | 3.5244 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.563B |
Beta (3-Years) | 1.01 |
Revenue Growth (ttm) | -38.19% |
Net Profit Margin (ttm) | -339.32% |
Return On Assets (ttm) | -47.57% |
EPS (ttm) | -0.46 |
PE Ratio (ttm) | -7.3 |
Dividend Yield | % |
Asset Description: | Arbutus Biopharma Corporation |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-12-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
3.427 | 3.528 | 3.595 | 3.696 | 3.864 | 4.032 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.